Market Overview:
The global central nervous system disorders therapeutics market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of central nervous system disorders, rising awareness about these disorders, and advancements in treatment options. The global central nervous system disorders therapeutics market is segmented on the basis of type into depression, multiple sclerosis (MS), bipolar disorder, schizophrenia, epilepsy, Alzheimer's disease (AD), Parkinson's disease (PD), and others. The depression segment is expected to account for the largest share of the global central nervous system disorders therapeutics market in 2018. This segment is also projected to grow at a high CAGR during the forecast period from 2018 to 2030. This growth can be attributed to increasing awareness about depression and its symptoms among people across all age groups and rising incidence of depression worldwide. On the basis of application, the global central nervous system disorders therapeutics market is divided into clinics and hospitals segments.
Product Definition:
Central Nervous System Disorders Therapeutics is the study and treatment of diseases that affect the central nervous system. It is important because it can help improve the quality of life for people who suffer from these diseases.
Depression:
Depression is a mood disorder characterized by low self-esteem, diminished interest in activities that used to bring pleasure, and irritability or anger when things do not go the way one wants them to. It is also associated with changes in sleep patterns, loss of appetite and/or weight, fatigue (trouble sleeping), concentration problems as well as physical symptoms such as stomach ache or pain; headache; joint pain; muscle tension; etc.
MS:
Multiple Sclerosis (MS) is a chronic disease of the central nervous system, which affects many body functions. The most common symptoms include relapses and attacks, unusual sensations and tingling or pain in parts or entire of the body, speech problems, vision problems. There are two types of MS: Primary (idiopathic) and secondary multiple sclerosis.
Application Insights:
The clinical segment dominated the global central nervous system disorders therapeutics market in 2017. This is attributed to factors such as an increase in prevalence of neurological conditions and growing awareness amongst patients regarding treatment options. For instance, according to WHO, approximately 1 billion people suffer from some form of mental illness globally which accounts for 3.4% of the total population. Similarly, as per a study published by National Center for Biotechnology Information (NCBI) in 2015, around 642 million adults were suffering from some form of depression across the globe which was an increase from 489 million reported in 2008 and 393 million reported in 2000 respectively.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of key players, favorable government initiatives, and increasing prevalence of CNS disorders are some factors driving the regional market. Asia Pacific is expected to grow at a lucrative rate during the forecast period owing to rising disposable income, improving healthcare infrastructure and growing awareness about early diagnosis & treatment options for CNS disorders. Moreover, increasing investments by major pharmaceutical companies for R&D activities in this region will drive growth further. In addition, launch of new products by key players such as Johnson & Johnson; Merck & Co., Inc.; Allergan Plc; Pfizer Inc.
Growth Factors:
- Increasing incidence of neurological disorders: The global incidence of neurological disorders is increasing at a significant rate. This is mainly due to the aging population, which is more susceptible to these diseases. The Central Nervous System Disorders Therapeutics market is expected to benefit from this trend.
- Growing awareness about CNS disorders: There is a growing awareness among people about Central Nervous System Disorders and their treatment options. This has led to an increase in the demand for CNS disorder therapies.
- Advances in technology: The field of neuroscience is rapidly evolving, with new technologies being developed every day for the diagnosis and treatment of CNS disorders. This will help drive growth in the Central Nervous System Disorders Therapeutics market in the coming years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Central Nervous System Disorders Therapeutics Market Research Report
By Type
Depression, MS, bipolar disorder, schizophrenia, epilepsy, AD, Parkinson' s, others
By Application
Clinicals, Hospitials
By Companies
Eli Lilly, GlaxoSmithKline, Janssen Pharmaceuticals, Novartis, Pfizer
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
232
Number of Tables & Figures
163
Customization Available
Yes, the report can be customized as per your need.
Global Central Nervous System Disorders Therapeutics Market Report Segments:
The global Central Nervous System Disorders Therapeutics market is segmented on the basis of:
Types
Depression, MS, bipolar disorder, schizophrenia, epilepsy, AD, Parkinson' s, others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinicals, Hospitials
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Eli Lilly
- GlaxoSmithKline
- Janssen Pharmaceuticals
- Novartis
- Pfizer
Highlights of The Central Nervous System Disorders Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Depression
- MS
- bipolar disorder
- schizophrenia
- epilepsy
- AD
- Parkinson' s
- others
- By Application:
- Clinicals
- Hospitials
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Central Nervous System Disorders Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Central nervous system disorders therapeutics is a field of pharmaceuticals that focus on the treatment of central nervous system (CNS) diseases. CNS diseases can be broadly classified into two categories: primary and secondary. Primary CNS diseases are those that originate from within the brain or spinal cord, while secondary CNS diseases are caused by external factors such as infection, injury, or disease.
Some of the key players operating in the central nervous system disorders therapeutics market are Eli Lilly, GlaxoSmithKline, Janssen Pharmaceuticals, Novartis, Pfizer.
The central nervous system disorders therapeutics market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Central Nervous System Disorders Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Central Nervous System Disorders Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Central Nervous System Disorders Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Central Nervous System Disorders Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Central Nervous System Disorders Therapeutics Market Size & Forecast, 2020-2028
4.5.1 Central Nervous System Disorders Therapeutics Market Size and Y-o-Y Growth
4.5.2 Central Nervous System Disorders Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Depression
5.2.2 MS
5.2.3 bipolar disorder
5.2.4 schizophrenia
5.2.5 epilepsy
5.2.6 AD
5.2.7 Parkinson' s
5.2.8 others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Clinicals
6.2.2 Hospitials
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Central Nervous System Disorders Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Central Nervous System Disorders Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Depression
9.6.2 MS
9.6.3 bipolar disorder
9.6.4 schizophrenia
9.6.5 epilepsy
9.6.6 AD
9.6.7 Parkinson' s
9.6.8 others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Clinicals
9.10.2 Hospitials
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Depression
10.6.2 MS
10.6.3 bipolar disorder
10.6.4 schizophrenia
10.6.5 epilepsy
10.6.6 AD
10.6.7 Parkinson' s
10.6.8 others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Clinicals
10.10.2 Hospitials
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Depression
11.6.2 MS
11.6.3 bipolar disorder
11.6.4 schizophrenia
11.6.5 epilepsy
11.6.6 AD
11.6.7 Parkinson' s
11.6.8 others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Clinicals
11.10.2 Hospitials
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Depression
12.6.2 MS
12.6.3 bipolar disorder
12.6.4 schizophrenia
12.6.5 epilepsy
12.6.6 AD
12.6.7 Parkinson' s
12.6.8 others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Clinicals
12.10.2 Hospitials
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Depression
13.6.2 MS
13.6.3 bipolar disorder
13.6.4 schizophrenia
13.6.5 epilepsy
13.6.6 AD
13.6.7 Parkinson' s
13.6.8 others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Clinicals
13.10.2 Hospitials
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Central Nervous System Disorders Therapeutics Market: Competitive Dashboard
14.2 Global Central Nervous System Disorders Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Eli Lilly
14.3.2 GlaxoSmithKline
14.3.3 Janssen Pharmaceuticals
14.3.4 Novartis
14.3.5 Pfizer
